SCHEMBL25186567

SCHEMBL25186567

COC(=O)N(C1c2ccccc2-c2ccccc21)[C@@H](CCc1ccc(C(F)(F)F)cc1)C(=O)O

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ FFAR1 O14842 1/20 0.39
▸ FFAR4 Q5NUL3 1/20 0.39
▸ PTGDR2 Q9Y5Y4 2/20 0.38
▸ MEN1 O00255 5/20 0.38
▸ KMT2A Q03164 5/20 0.38
▸ TMEM97 Q5BJF2 1/20 0.37
▸ PPARA Q07869 2/20 0.37
▸ PPARD Q03181 1/20 0.37
▸ PLAAT3 P53816 1/20 0.37
▸ PLAAT5 Q96KN8 1/20 0.37
▸ PLAAT2 Q9NWW9 1/20 0.37
▸ PLAAT4 Q9UL19 1/20 0.37
▸ LTA4H P09960 1/20 0.37
▸ EPHX2 P34913 1/20 0.37
▸ ATM Q13315 1/20 0.37
▸ CETP P11597 1/20 0.37
▸ MCHR1 Q99705 1/20 0.36
▸ PPARG P37231 1/20 0.36
▸ MMP2 P08253 1/20 0.36
▸ MMP3 P08254 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25185758 0.90 PPARG (0.42) PTGDR2MEN1KMT2APPARAEPHX2
SCHEMBL25173040 0.89 PRSS1 (0.39) MEN1KMT2APRSS1CTSGCTRB1
SCHEMBL25185680 0.89 KMT2A (0.40) FFAR1FFAR4MEN1KMT2AATM
SCHEMBL25178739 0.87 FFAR1 (0.36) FFAR1FFAR4MEN1KMT2APLAAT3
SCHEMBL30510294 0.86 PPARG (0.41) FFAR1FFAR4MEN1KMT2APPARA
SCHEMBL25178770 0.86 PPARG (0.41) FFAR1FFAR4MEN1KMT2APPARA
SCHEMBL25178578 0.85 PPARD (0.37) FFAR1PPARAPPARDPPARG
SCHEMBL25185656 0.85 MEN1 (0.33) PTGDR2MEN1KMT2AATMCETP
SCHEMBL30510323 0.85 MEN1 (0.33) PTGDR2MEN1KMT2AATMCETP
SCHEMBL25182303 0.85 MMP7 (0.36) FFAR1FFAR4MEN1KMT2APPARA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 — — US disclosed
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-12-05 — — US disclosed
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-09 — — US disclosed
EP-4316503-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-07 — — EP disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS FFAR1 3629/4885FFAR4 3700/4885PTGDR2 3740/4885
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS FFAR1 3629/4885FFAR4 3700/4885PTGDR2 3740/4885
US-20240148821-A1 PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND VIP, IAPP, KRAS FFAR1 3115/4885FFAR4 2114/4885PTGDR2 2053/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS FFAR1 3629/4885FFAR4 3700/4885PTGDR2 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback